Literature DB >> 10660482

Mutations of the HFE gene and the risk of hepatocellular carcinoma.

O Racchi1, R Mangerini, D Rapezzi, G F Gaetani, M T Nobile, A Picciotto, A M Ferraris.   

Abstract

The discovery of the C282Y and H63D point mutations in the hereditary hemochromatosis-associated HFE gene allows us to study the molecular basis of congenital and acquired iron overload disorders. In hereditary hemochromatosis an increased frequency of the C282Y and, to a lesser extent, of the H63D mutations has been established, but their role in other conditions associated with iron overload and their prevalence in the normal population are still under investigation. We sought to determine the presence of such mutations, and their possible involvement in the multi-step neoplastic transformation of the hepatocytes, in patients diagnosed with hepatocellular carcinoma, a frequent complication of iron-induced liver cirrhosis occurring in untreated hereditary hemochromatosis subjects. The frequency of the C282Y and H63D mutations was determined in DNA from 12 patients with hepatocellular carcinoma and with no clinical signs of hereditary hemochromatosis. The frequency of the mutations was also determined in 130 normal subjects. A germline C282Y mutation was found in none of the hepatocellular carcinoma patients; the frequency of the H63D mutation was not increased, compared to the 130 controls. The allele frequencies of the C282Y and H63D mutations in the normal population were 0.042 and 0.185, respectively. In conclusion, we suggest that the hereditary hemochromatosis-related mutations of the HFE gene do not play a significant role in the pathogenesis of hepatocellular carcinoma. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10660482     DOI: 10.1006/bcmd.1999.0263

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  9 in total

1.  Epidemiology of primary and secondary liver cancers.

Authors:  Ashwin Ananthakrishnan; Veena Gogineni; Kia Saeian
Journal:  Semin Intervent Radiol       Date:  2006-03       Impact factor: 1.513

2.  Association between C282Y and H63D mutations of the HFE gene with hepatocellular carcinoma in European populations: a meta-analysis.

Authors:  Fei Jin; Li-Shuai Qu; Xi-Zhong Shen
Journal:  J Exp Clin Cancer Res       Date:  2010-03-02

Review 3.  HFE gene in primary and secondary hepatic iron overload.

Authors:  Giada Sebastiani; Ann-P Walker
Journal:  World J Gastroenterol       Date:  2007-09-21       Impact factor: 5.742

4.  Hepatocellular carcinoma and the penetrance of HFE C282Y mutations: a cross sectional study.

Authors:  Gavin Willis; Vicky Bardsley; Ian W Fellows; Ray Lonsdale; Jennie Z Wimperis; Barbara A Jennings
Journal:  BMC Gastroenterol       Date:  2005-06-01       Impact factor: 3.067

Review 5.  Evidence for the Influence of the Iron Regulatory MHC Class I Molecule HFE on Tumor Progression in Experimental Models and Clinical Populations.

Authors:  Cody Weston; James Connor
Journal:  Transl Oncogenomics       Date:  2014-12-04

6.  The risk of new-onset cancer associated with HFE C282Y and H63D mutations: evidence from 87,028 participants.

Authors:  Yang-Fan Lv; Xian Chang; Rui-Xi Hua; Guang-Ning Yan; Gang Meng; Xiao-Yu Liao; Xi Zhang; Qiao-Nan Guo
Journal:  J Cell Mol Med       Date:  2016-02-19       Impact factor: 5.310

7.  HFE C282Y and H63D in adults with malignancies in a community medical oncology practice.

Authors:  James C Barton; Luigi F Bertoli; Ronald T Acton
Journal:  BMC Cancer       Date:  2004-02-10       Impact factor: 4.430

8.  The evolutionary adaptation of the C282Y mutation to culture and climate during the European Neolithic.

Authors:  Kathleen M Heath; Jacob H Axton; John M McCullough; Nathan Harris
Journal:  Am J Phys Anthropol       Date:  2016-01-22       Impact factor: 2.868

9.  Association between the HFE C282Y, H63D Polymorphisms and the Risks of Non-Alcoholic Fatty Liver Disease, Liver Cirrhosis and Hepatocellular Carcinoma: An Updated Systematic Review and Meta-Analysis of 5,758 Cases and 14,741 Controls.

Authors:  Qing Ye; Bao-Xin Qian; Wei-Li Yin; Feng-Mei Wang; Tao Han
Journal:  PLoS One       Date:  2016-09-22       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.